Impact of Betamethasone Pretreatment on Engrafment of Cord Blood-Derived Hematopoietic Stem Cells

• Published in: Archivum Immunologiae et Therapiae Experimentalis 2023-12, Vol.71 (1), p.1-1, Article 1
• Main Authors: Perna-Barrull, David, Gomez-Muñoz, Laia, Rodriguez-Fernandez, Silvia, Gieras, Anna, Ampudia-Carrasco, Rosa M., Almenara-Fuentes, Lidia, Risueño, Ruth M., Querol, Sergi, Tolosa, Eva, Vives-Pi, Marta
• Format: Article
• Language: English
• Subjects: Animals; Antigens, CD34; Betamethasone - therapeutic use; Biomedical and Life Sciences; Biomedicine; Bone marrow; CD34 antigen; Cord blood; Cord Blood Stem Cell Transplantation; CXCR4 protein; Engraftment; Fetal Blood; Flow cytometry; Fluticasone; Glucocorticoids; Glucocorticoids - pharmacology; Glucocorticoids - therapeutic use; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histocompatibility antigen HLA; Homeostasis; Immune system; Immunology; Lymphocytes T; Malignancy; Mice; Mice, Inbred NOD; Mice, SCID; Original; Original Article; Peripheral blood; Pharmacology/Toxicology; Phenotypes; Stem cell transplantation; Stem cells; Transcriptomics; Umbilical cord
• ISSN: 0004-069X; 1661-4917
• DOI: 10.1007/s00005-022-00666-5

Hematopoietic stem cell (HSC) transplantation is crucial to cure hematologic malignancies. Umbilical cord blood (UCB) is a source of stem cells, but 90% of UCB units are discarded due to low cellularity. Improving the engraftment capacities of CD34 + stem cells would allow the use of UCB that were so far rejected. Betamethasone induces long-term transcriptomic and epigenomic changes in immune cells through glucocorticoid receptor. We hypothesize that discarded UCB could be used owing to improvements induced by betamethasone. Isolated CD34 + HSC from UCB were exposed to the synthetic glucocorticoids betamethasone and fluticasone for 20 h, and cell phenotype was determined before transplantation. NSG mice were sub-lethally irradiated (1 Gy or 2 Gy) 6 h before intravenously transferring 2–5 × 10 5 CD34 + HSC. The peripheral blood engraftment levels and the leukocyte subsets were followed up for 20 weeks using flow cytometry. At end point, the engraftment and leukocyte subsets were determined in the spleen and bone marrow. We demonstrated that betamethasone has surprising effects in recovering immune system homeostasis. Betamethasone and fluticasone increase CXCR4 and decrease HLA class II and CD54 expression in CD34 + HSCs. Both glucocorticoids-exposed cells showed a similar engraftment in 2 Gy-irradiated NSG mice. Interestingly, betamethasone-exposed cells showed enhanced engraftment in 1 Gy-irradiated NSG mice, with a trend to increase regulatory T cell percentage when compared to control. Betamethasone induces alterations in CD34 + HSCs and improve the engraftment, leading to a faster immune system recovery, which will contribute to engrafted cells survival.